Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 11/2023

Open Access 22-09-2023 | Shingles | Original Research

Burden of Herpes Zoster Among Patients with Psoriasis in the United States

Authors: David Singer, Philippe Thompson-Leduc, Siyu Ma, Deepshekhar Gupta, Wendy Y. Cheng, Selvam R. Sendhil, Manasvi Sundar, Ella Hagopian, Nikita Stempniewicz, Mei Sheng Duh, Sara Poston

Published in: Dermatology and Therapy | Issue 11/2023

Login to get access

Abstract

Introduction

Patients with psoriasis (PsO) are at increased risk of herpes zoster (HZ), but recent data on the incidence of HZ among patients with PsO and the impact of HZ on healthcare resource use (HRU) and costs for patients with PsO have not been described.

Methods

This retrospective, longitudinal, cohort study estimated HZ incidence in cohorts of adults with vs without PsO (PsO + vs PsO–) and HRU and costs among those with PsO, with vs without HZ (PsO + /HZ + vs PsO + /HZ–) using Optum’s de-identified Clinformatics Data Mart Database during 2015–2020. Patients with psoriatic arthritis were excluded from all four cohorts. Comparisons between cohorts used generalized linear models to adjust outcomes based on various baseline characteristics.

Results

The incidence rate of HZ was significantly higher in the PsO + (n = 144,115) vs PsO– (n = 23,837,237) cohorts at 11.35 vs 7.67 per 1000 patient-years; adjusted incidence rate ratio (aIRR): 1.21, 95% confidence interval (CI): 1.16–1.25. HRU (outpatient, emergency department, and inpatient) was significantly higher in the PsO + /HZ + (n = 1859) vs PsO + /HZ– (n = 78,664) cohorts during 1 month and 3 months after HZ diagnosis (e.g., outpatient visits during month: 2.83 vs 1.30 per patient; aIRR: 1.96; 95% CI 1.86–2.06). Mean all-cause costs were also significantly higher in the PsO + /HZ + vs PsO + /HZ– cohort during both month ($5020 vs $2715 per patient; adjusted cost difference: $1390; 95% CI $842–$1964) and 3 months ($12,305 vs $8256; adjusted cost difference: $1422; 95% CI $280–$2889) after HZ diagnosis.

Conclusion

These findings show the increased incidence of HZ among patients with PsO and the clinical and economic burdens of HZ in this population. Considering the high prevalence of PsO, insights into the impact of HZ in these patients provide valuable evidence to inform clinical decision-making.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
Lee YW, Park EJ, Kwon IH, Kim KH, Kim KJ. Impact of psoriasis on quality of life: relationship between clinical response to therapy and change in health-related quality of life. Ann Dermatol. 2010;22(4):389–96. CrossRefPubMedPubMedCentral
2.
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–6. CrossRefPubMed
3.
Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–70. CrossRefPubMed
4.
Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81(3):775–804. CrossRefPubMed
5.
Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–86. CrossRefPubMed
6.
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72. CrossRefPubMed
7.
8.
Min C, Yoo DM, Kim M, Choi HG. Increased risk of herpes zoster in patients with psoriasis: a longitudinal follow-up study using a national sample cohort. Australas J Dermatol. 2021;62(2):183–9. CrossRefPubMed
9.
Tsai SY, Chen HJ, Lio CF, et al. Increased risk of herpes zoster in patients with psoriasis: a population-based retrospective cohort study. PLoS ONE. 2017;12(8): e0179447. CrossRefPubMedPubMedCentral
10.
Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J Invest Dermatol. 2018;138(8):1726–35. CrossRefPubMedPubMedCentral
11.
Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325–34. CrossRefPubMed
12.
Zou A, Chen Y, Shi N, Ye Y. Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Medicine (Baltimore). 2021;100(40): e27368. CrossRefPubMed
13.
Hagberg KW, Persson R, Vasilakis-Scaramozza C, et al. Herpes zoster, Hepatitis C, and tuberculosis risk with apremilast compared to biologics, DMARDs and corticosteroids to treat psoriasis and psoriatic arthritis. Clin Epidemiol. 2020;12:153–61. CrossRefPubMedPubMedCentral
14.
Shalom G, Zisman D, Bitterman H, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatol. 2015;151(5):533–8. CrossRefPubMed
15.
Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019;81(1):102–10. CrossRefPubMed
16.
Chiu HY, Hung YT, Huang SW, Huang YH. Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis. Ther Adv Chronic Dis. 2022;13:20406223221091188. CrossRefPubMedPubMedCentral
17.
18.
Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37. CrossRefPubMedPubMedCentral
19.
Matthews S, De Maria A, Passamonti M, et al. The economic burden and impact on quality of life of herpes zoster and postherpetic neuralgia in individuals aged 50 years or older in Italy. Open Forum Infect Dis. 2019;6(2):ofz007. CrossRefPubMedPubMedCentral
20.
21.
Curran D, Callegaro A, Fahrbach K, et al. Meta-Regression of Herpes Zoster Incidence Worldwide. Infect Dis Ther. 2022;11(1):389–403. CrossRefPubMed
22.
Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: Population based case-control study. BMJ. 2014;348: g2911. CrossRefPubMedPubMedCentral
23.
Singer D, Thompson-Leduc P, Poston S, et al. Incidence of herpes zoster in patients with rheumatoid arthritis in the United States: a retrospective cohort study. J Rheumatol 2023;50(7):873–80. CrossRefPubMed
24.
Singer D, Thompson-Leduc P, Gupta D, et al. Incidence and risk of herpes zoster in patients with ulcerative colitis and Crohn’s disease in the USA. Gastroenterol Rep (Oxf). 2023;11:goad016. CrossRefPubMedPubMedCentral
25.
Muñoz-Quiles C, Lopez-Lacort M, Diez-Domingo J. Risk and impact of herpes zoster among COPD patients: a population-based study, 2009–2014. BMC Infect Dis. 2018;18(1):203. CrossRefPubMedPubMedCentral
26.
Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30 ( quiz CE2-4). PubMed
27.
Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–8. CrossRefPubMedPubMedCentral
28.
Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the advisory committee on Immunization Practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80–4. CrossRefPubMedPubMedCentral
29.
30.
Merola JF, Dennis N, Chakravarty SD, et al. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA - a retrospective study of claims data from 2009 to 2020. Clin Rheumatol. 2021;40(10):4061–70. CrossRefPubMed
31.
Al Sawah S, Foster SA, Goldblum OM, et al. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ. 2017;20(9):982–90. CrossRefPubMed
32.
Singer D, Thompson-Leduc P, Poston S, et al. Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims. Rheumatol Ther. 2023;10(4):933–50. CrossRefPubMedPubMedCentral
33.
Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012. BMJ Open. 2018;8(6): e020528. CrossRefPubMedPubMedCentral
34.
Feldman SR, Zhao Y, Shi L, Tran MH. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(10):874–88. PubMed
35.
Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc. 2009;84(9):787–94. CrossRefPubMedPubMedCentral
36.
Meyers JL, Madhwani S, Rausch D, Candrilli SD, Krishnarajah G, Yan S. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States. Hum Vaccine Immunother. 2017;13(8):1861–72. CrossRef
37.
Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Vaccine. 2018;36(45):6810–8. CrossRefPubMed
38.
Ghaswalla P, Thompson-Leduc P, Cheng WY, et al. Increased health care resource utilization and costs associated with herpes zoster among patients aged ≥50 years with chronic obstructive pulmonary disease in the United States. Chronic Obstr Pulm Dis. 2021;8(4):502–16. PubMedPubMedCentral
39.
Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc. 2011;86(12):1146–53. CrossRefPubMedPubMedCentral
40.
Metadata
Title
Burden of Herpes Zoster Among Patients with Psoriasis in the United States
Authors
David Singer
Philippe Thompson-Leduc
Siyu Ma
Deepshekhar Gupta
Wendy Y. Cheng
Selvam R. Sendhil
Manasvi Sundar
Ella Hagopian
Nikita Stempniewicz
Mei Sheng Duh
Sara Poston
Publication date
22-09-2023
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 11/2023
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-023-00988-y

Other articles of this Issue 11/2023

Dermatology and Therapy 11/2023 Go to the issue

Brief Report

Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data

Letter

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Original Research

Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database

Original Research

Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis

Review

Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature

Brief Report

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
Webinar | 08-11-2023 | 18:00 (CET)

Keynote Webinar | Spotlight on Diet and Diabetes

Watch now

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.
Prof. Mike Lean
Prof. Falko Sniehotta
Image Credits